Biology of Blood and Marrow Transplantation
Volume 14, Issue 7 , Pages 766-774 , July 2008

Evaluation of Angiopoietins and Cell-Derived Microparticles after Stem Cell Transplantation

  • Shosaku Nomura

      Affiliations

    • Division of Hematology, Kishiwada City Hospital, Osaka, Japan
    • Corresponding Author InformationCorrespondence and reprint requests: Shosaku Nomura, MD, Division of Hematology, Kishiwada City Hospital, 1001, Gakuhara-cho, Kishiwada, Osaka 596-8501, Japan.
    • ,
  • Kazuyoshi Ishii

      Affiliations

    • Division of Hematology, Kishiwada City Hospital, Osaka, Japan
    • ,
  • Norihito Inami

      Affiliations

    • Second Department of Internal Medicine, Kansai Medical University, Moriguchi, Osaka, Japan
    • ,
  • Yutaka Kimura

      Affiliations

    • Second Department of Internal Medicine, Kansai Medical University, Moriguchi, Osaka, Japan
    • ,
  • Nobuhiko Uoshima

      Affiliations

    • Department of Internal Medicine, Matsushita Memorial Hospital, Moriguchi, Osaka, Japan
    • ,
  • Hiroyuki Ishida

      Affiliations

    • Department of Pediatrics, Matsushita Memorial Hospital, Moriguchi, Osaka, Japan
    • ,
  • Takao Yoshihara

      Affiliations

    • Department of Pediatrics, Matsushita Memorial Hospital, Moriguchi, Osaka, Japan
    • ,
  • Fumiaki Urase

      Affiliations

    • Department of Hematology, Kinki University, Sayama, Osaka, Japan
    • ,
  • Yasuhiro Maeda

      Affiliations

    • Department of Hematology, Kinki University, Sayama, Osaka, Japan
    • ,
  • Kunio Hayashi

      Affiliations

    • Division of Hematology, Keihanna Hospital, Hirakata, Osaka, Japan

Received 3 February 2008 ,Accepted 10 April 2008.

References 

  1. Roberts MM, To LB, Gillis D, et al. Immune reconstitution following peripheral blood stem cell transplantation, autologous bone marrow transplantation and allogenic bone marrow transplantation. Bone Marrow Transplant. 1993;12:469–475
  2. Juttner CA, To LB, Ho J, et al. Early lympho-hematopoietic recovery after autografting using peripheral blood stem cell in acute nonlymphoblastic leukemia. Transplant Proc. 1998;20:40–42
  3. Rowbottom AW, Riches PG, Downie C, Hobbs JR. Monitoring cytokine production in peripheral blood during acute graft-versus-host disease following allogenic bone marrow transplantation. Bone Marrow Transplant. 1993;12:635–641
  4. Testa S, Manna A, Porcellini A, et al. Increased plasma level of vascular endothelial glycoprotein thrombomodulin as an early indicator of endothelial damage in bone marrow transplantation. Bone Marrow Transplant. 1996;18:383–388
  5. Nishida T, Hamaguchi M, Hirabayashi N, et al. Intestinal thrombotic microangiopathy after allogenic bone marrow transplantation: a clinical imitator of acute enteric graft-versus-host disease. Bone Marrow Transplant. 2004;33:1143–1150
  6. Krenger W, Hill GR, Ferrara JL. Cytokine cascades in acute graft- versus-host disease. Transplantation. 1997;64:553–558
  7. Schmaltz C, Alpdogan O, Horndasch KJ, et al. Differential use of Fas ligand and perforin cytotoxic pathway by donor T-cells in graft-versus-host disease and graft-versus-leukemia effect. Blood. 2001;97:2886–2895
  8. Kagi D, Vignaux F, Ledermann B, et al. Fas and perforin pathways as major mechanisms of T-cell-mediated cytotoxicity. Science. 1994;265:528–530
  9. Lowin B, Hahne M, Mattmann C, Tachopp J. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature. 1994;370:650–652
  10. Nagata S. Apoptosis by death factor. Cell. 1997;88:355–365
  11. Das H, Imoto S, Murayama T, et al. Levels of soluble Fas and FasL gene expression during the development of graft-versus-host disease in DLT-treated patients. Br J Haematol. 1999;104:795–800
  12. Takada S, Hatsumi N, Saito T, et al. Two cases of chronic graft-versus-host disease with elevated levels of soluble Fas ligand in serum. Am J Hematol. 2000;64:133–136
  13. Jaksch M, Uzunel M, Martinez Cangana G, Remberger M, Mattsson J. Increased of immune transcript in patients with acute GVHD after allogenic stem cell transplantation. Bone Marrow Transplant. 2003;31:183–190
  14. Freyssinet JM. Cellular microparticles: what are they bad or good for?. J Thromb Haemost. 2003;1:1655–1662
  15. Jy W, Horstmann LL, Jimenez JJ, et al. Measuring circulating cell-derived microparticles. J Thromb Haemost. 2004;2:1842–1851
  16. Nomura S, Ishii K, Kanazawa S, et al. Significance of elevation in cell-derived microparticles after allogenic stem cell transplantation: transient elevation of platelet-derived microparticles in TMA/TTP. Bone Marrow Transplant. 2005;36:921–922
  17. Dickinson AM, Wang XN, Sviland L, et al. I situ dissection of the graft-versus-host activities of cytotoxic T-cells specific for minor histocompatibility antigens. Nat Med. 2002;8:410–414
  18. Woywodt A, Scheer J, Hambach L, et al. Circulating endothelial cells as a marker of endothelial damage in allogenic hematopoietic stem cell transplantation. Blood. 2004;103:3603–3605
  19. Dumler JS, Beschorner WE, Farmer ER, Gennaro KADi, Saral R, Santos GW. Endothelial-cell injury in cutaneous acute graft-versus-host disease. Am J Pathol. 1989;135:1097–1103
  20. Marelli-Berg FM, James MJ, Dangerfield J, et al. Cognate recognition of the endothelium induces HY-specific CD8+ T-lymphocyte transendothelial migration (diapedesis) in vivo. Blood. 2004;103:3111–3116
  21. Ertault-Daneshpouy M, Leboeuf C, Lemann M, et al. Pericappillary hemorrhage as sriterion of serve human digestive graft-versus-host disease. Blood. 2004;103:4681–4684
  22. Kummer M, Lev A, Reiter Y, Biedermann BC. Vascular endothelial cells have impaired capacity to present immunodominant, antigenic paptides: a mechanism of cell type-specific immune escape. J Immunol. 2005;174:1947–1953
  23. Davis S, Aldrich TH, Jones PF, et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell. 1996;87:1161–1169
  24. Suri C, Jones PF, Patan S, et al. Requisite role of angiopoietin-1, a ligand for the TIE receptor, during embryonic angiogenesis. Cell. 1996;87:1171–1180
  25. Papapetropoulos A, Garcia-Cardena G, Dengler TJ, et al. Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors. Lab Invest. 1999;79:213–223
  26. Kwak HJ, So JN, Lee SJ, Kim I, Koh GY. Angiopoietin-1 is an apoptosis survival factor for endothelial cells. FEBS Lett. 1999;79:213–223
  27. Thurston G, Suri C, Smith K, et al. Leakage-resistant blood vessels in mice transgenically overexpressing anfiopoietin-1. Science. 1999;286:2511–2514
  28. Thurston G, Rudge JS, Ioffe E, et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med. 2000;6:460–463
  29. Gamble JR, Trew J, Trezise L, et al. Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions. Circ Res. 2000;87:603–607
  30. Kim I, Moon SO, Park SK, Chae SW, Koh GY. Angiopoietin-1 reduces VEGF-stimulated leukocyte adhesion to endothelial cells by reducing ICAM-1, VCAM-1, and E-slectin expression. Circ Res. 2001;89:477–479
  31. Kim I, Oh JL, Ryu YS, et al. Angiopoietin-1 negatively regulates expression and activity of tissue factor in endothelial cells. FASEB J. 2002;16:126–128
  32. Pizurki L, Zhou Z, Glynos K, Roussos C, Papapetropoulos A. Angiopoietin-1 inhibits endothelial permeability, neutrophil adherence and IL-8 production. Br J Pharmacol. 2003;139:329–336
  33. Lim HS, Blann AD, Chong AY, Freestone B, Lip GYH. Plasma vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in diabetes. Diabetes Care. 2004;27:2918–2924
  34. Lim HS, Lip GY, Blann AD. Angiopoietin-1 and angiopoietin-2 in diabetes mellitus: relationship to VEGF, glycaemic control, endothelial damage/dysfuntion and atherosclerosis. Atherosclerosis. 2005;180:113–118
  35. McCarter SD, Lai PFH, Suen RS, Stewart DJ. Regulation of endothelin-1 by angiopoietin-1: implications for inflammation. Exp Biol Med. 2006;231:985–991
  36. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. J Clin Invest. 1973;52:2745–2756
  37. Nomura S, Shouzu A, Omoto S, Nishikawa M, Iwasaka T, Fukuhara S. Activated platelet and oxidized LDL induce endothelial membrane vesiculation: clinical significance of endothelial cell-derived microparticles in patients with type 2 diabetes. Clin Appl Thromb Hemost. 2004;10:205–215
  38. Ferrara JL, Cooke KR, Pan L, Krenger W. The immunopathophysiol of acute graft-versus-host-disease. Stem Cells. 1996;14:473–489
  39. Schots R, Kaufman L, Van Riet I, et al. Proinflammatory cytokines and their role in the development of major transplant-related complications in the early phase after allogenic bone marrow transplantation. Leukemia. 2003;17:1150–1156
  40. Grimm J, Zeller W, Zander AR. Soluble interleukin-2 receptor serum levels after allogenic bone marrow transplantations as a marker for GVHD. Bone Marrow Transplant. 1998;21:29–32
  41. Liem LM, van Houwelingen HC, Goulmy E. Serum cytokine levels after HLA-identical bone marrow transplantation. Transplantation. 1998;66:863-718
  42. Min CK, Lee MY, Min DJ, et al. The kinetics of circulating cytokines including IL-6, TNF-α, IL-8 and IL-10 following allogenic hematopoietic ctem cell transplantation. Bone Marrow Transplant. 2001;28:935–940
  43. Lee WY, Baek KH, Rhee EJ, et al. Impact of circulating bone-resorbing cytokines on the subsequent bone loss following bone marrow transplantation. Bone Marrow Transplant. 2004;34:89–94
  44. Jimenez JJ, Jy W, Mauro LM, Horstman LL, Soderland C, Ahn YS. Endothelial microparticles released in thrombotic thrombocytopenic purpura express von Willebrand factor and markers of endothelial activation. Br J Haematol. 2003;123:896–902
  45. Pihusch V, Rank A, Steber R, et al. Endothelial cell-derived microparticles in allogeneic hematopoietic stem cell recipients. Transplantation. 2006;81:1405–1409
  46. Kanda Y, Tanaka Y, Shirakawa K, et al. Increased soluble Fas-ligand in sera of bone marrow transplant recipients with acute graft-versus-host disease. Bone Marrow Transplant. 1998;22:751–754
  47. Kim I, Moon S, Park SK, et al. Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Circ Res. 2000;86:24–29
  48. Nomura S, Ishii K, Kanazawa S, et al. Role of platelet-derived chemokines (RANTES and ENA-78) after stem cell transplantation. Transplant Immunol. 2006;15:247–253
  49. Li JJ, Huang YQ, Basch R, Karpatkin S. Thrombin induces the release of angiopoietin-1 from platelets. Thromb Haemost. 2001;85:204–206
  50. Nadar S, Blann AD, Lip GY. Plasma and platelet-derived vascular endothelial growth factor and angiopoietin-1 in hypertension: effect of antihypertensive therapy. J Intern Med. 2004;256:331–337
  51. Nadar S, Blann AD, Lip GY. Effects of aspirin on intra-platelet vascular endothelial growth factor, angiopoietin, and p-selectin levels in hypertensive patients. Am J Hypertens. 2006;19:970–977
  52. Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie-2 that disrupts in vivo angiogenesis. Science. 1997;277:55–60
  53. Fiedler U, Scharpfenecker M, Koidl S, et al. The tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Plade bodies. Blood. 2004;103:4150–4156

PII: S1083-8791(08)00149-3

doi: 10.1016/j.bbmt.2008.04.005

Biology of Blood and Marrow Transplantation
Volume 14, Issue 7 , Pages 766-774 , July 2008

Article Tools

* Image Usage & Resolution